Are GLP-1 medications safe? What the evidence actually shows
Updated: Oct 1
What 'safe' means in medicine
No effective medicine is completely free of risk. The meaningful question is whether the expected benefits outweigh the known and potential harms for a particular patient.
GLP-1-based medicines have large clinical-trial programs and growing real-world experience. That gives clinicians a much clearer picture of common adverse effects, important contraindications and the situations that warrant closer monitoring.
The side effects patients hear about most
The most common adverse effects are gastrointestinal, including nausea, vomiting, diarrhoea and constipation. They are often most noticeable during dose escalation and are commonly mild to moderate, although individual experiences vary.
Gradual titration exists for a reason. Moving through doses should be based on the specific product instructions and clinical response, rather than racing toward a higher dose.
Serious symptoms should not be normalised
Less common but potentially important complications can occur. Patients should know how to contact their treating team and when symptoms require urgent medical assessment rather than simply being told to 'push through'.
A responsible service should explain expected side effects, red flags and escalation pathways before treatment begins.
Who should be assessed carefully
Pregnancy, relevant gastrointestinal disease, previous pancreatitis or gallbladder problems, other medicines, diabetes therapy and other elements of medical history can influence treatment decisions. Product-specific contraindications also need to be checked.
This is why a clinical assessment is more than confirming a BMI.
Medication authenticity is part of safety
Global demand has led to falsified and substandard GLP-1 products. WHO has warned patients against unfamiliar or unverified sources. For injectable medicines, correct storage and handling are also important.
For an Indian patient, the safest pathway is a legitimate prescription, an authorised supply chain, clear product identification and appropriate follow-up.
References
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. PubMed
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025. PubMed
Endocrine Society of India. Clinical Practice Guidelines for the Evaluation and Management of Obesity in India: 2025 Update. PubMed Central (PMC)
CDSCO. Semaglutide/Wegovy regulatory recommendations and post-marketing surveillance in India.
Written and clinically reviewed by: Dr Saran Seker, MBBS (Aus), Chief Medical Officer
Last reviewed: September 2026
Comments